Sell-Side Offering Their Recommendations on Zimmer Biomet Holdings Inc (NYSE:ZBH), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sell-Side Offering Their Recommendations on Zimmer Biomet Holdings Inc (NYSE:ZBH), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

The Wall Street analysts who cover Zimmer Biomet Holdings Inc (NYSE:ZBH) shares are providing price target projections on the company. They project that the shares will move to $142.466 within the upcoming year. The number they've arrived at is calculated by, long known as a provider of top-notch investment research. From the analysts polled by Zack's Research, the highest estimate stands at $155 and the lowest is at $120 for the stock.

Analyst Ratings In View

Zacks provides the average brokerage recommendation (ABR) for thousands of stocks for institutions and retail investors alike. This the calculated average of the actual recommendations (strong buy, hold, sell etc.) made for a given stock. The ABR is typically displayed with decimals (e.g. 1.52) versus the Zacks Rank, which is only shown in whole numbers (e.g. 1, 2, 3, etc.). This simplifies brokerage recommendations, which can become complicated. Zimmer Biomet Holdings Inc (NYSE:ZBH)'s shares currently have an ABR of 1.75.

During this fiscal period, Street analysts are projecting $1.79 earnings/share. This represents the current Zacks consensus EPS. For the period which closed on 2016-06-30, Zimmer Biomet Holdings Inc (NYSE:ZBH) dialed in an EPS of $2.02, creating a Surprise Factor of 3.06% (the difference between analyst projections and actual numbers). Curious investors will be awaiting 2016-11-03, the date when Zimmer Biomet Holdings Inc (NYSE:ZBH) will release their quarterly results.

Research analysts covering Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) are projecting that the shares reach $475.187 within the next 12-18 months.  This is the consensus number derived from the 16 analyst reports taken into consideration. The most bullish, or aggressive analyst target pins the projected price at $668, while the most bearish, or conservative analyst sees the stock reaching $325.

Broker Rating Update on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Zacks provides analysts with an Average Broker Rating (or ABR), basing it on sell-side recommendations. Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) currently have an ABR of 2.39. This is based on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.  Moving to earnings estimates, for this current fiscal period, Wall Street analysts have projected that the company will post $2.27 earnings per share. This is the current Zacks consensus EPS which was calculated at the time of writing. Analysts will likely revise their estimates leading in to the actual results date.  

taking a look at the most recent period, which closed on 2016-06-30, Regeneron Pharmaceuticals, Inc. reported EPS of $2.11 for a surprise factor of 21.97%, calculated by being $0.38 away from analyst projections.

Investors will be marking their calendars for 2016-11-02, when the company is planning to release their quarterly results.